Patents by Inventor Thomas Sundberg

Thomas Sundberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10145848
    Abstract: The present invention includes compounds that are useful in perturbing or disrupting the function of a transmembrane or intracellular protein, whereby binding of the compounds to the transmembrane or intracellular protein induces proteasomal degradation of the transmembrane or intracellular protein. The present invention further includes a method of inducing proteasomal degradation of a transmembrane or intracellular protein. The present invention further includes a method of identifying or validating a protein of interest as a therapeutic target for treatment of a disease state or condition.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: December 4, 2018
    Assignee: Yale University
    Inventors: Craig M. Crews, Hyun Seop Tae, Ashley R. Schneekloth, Taavi Neklesa, Thomas Sundberg
  • Publication number: 20180221379
    Abstract: The present disclosure provides methods of treating and/or preventing inflammatory bowel disease (IBD) and graft-versus-host disease (GVHD) using salt-inducible kinase (SIK) inhibitors, such as macrocyclic SIK inhibitors of Formula (I), imidazolyl SIK inhibitors of Formula (II), and urea and carbamate SIK inhibitors of Formula (III-A) (e.g., urea and carbamate SIK inhibitors of Formula (III)).
    Type: Application
    Filed: December 19, 2017
    Publication date: August 9, 2018
    Applicants: Dana-Farber Cancer Institute, Inc., The Broad Institute, Inc., President and Fellows of Harvard College, The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Alykhan Shamji, Thomas Sundberg, Nathanael Gray, Ramnik Xavier, Stuart L. Schreiber, Hwan Geun Choi, Yanke Liang
  • Publication number: 20170307614
    Abstract: The present invention includes compounds that are useful in perturbing or disrupting the function of a transmembrane or intracellular protein, whereby binding of the compounds to the transmembrane or intracellular protein induces proteasomal degradation of the transmembrane or intracellular protein. The present invention further includes a method of inducing proteasomal degradation of a transmembrane or intracellular protein. The present invention further includes a method of identifying or validating a protein of interest as a therapeutic target for treatment of a disease state or condition.
    Type: Application
    Filed: April 6, 2017
    Publication date: October 26, 2017
    Inventors: Craig M. Crews, Hyun Seop Tae, Ashley R. Schneekloth, Taavi Neklesa, Thomas Sundberg
  • Publication number: 20170224700
    Abstract: The present disclosure provides methods of treating and/or preventing inflammatory bowel disease (IBD) and graft-versus-host disease (GVHD) using salt-inducible kinase (SIK) inhibitors, such as macrocyclic SIK inhibitors of Formula (I), imidazolyl SIK inhibitors of Formula (II), and urea and carbamate SIK inhibitors of Formula (III-A) (e.g., urea and carbamate SIK inhibitors of Formula (III)).
    Type: Application
    Filed: August 8, 2015
    Publication date: August 10, 2017
    Applicants: Dana-Farber Cancer Institute, Inc., The Broad Institute, Inc., President and Fellows of Harvard College, The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Alykhan Shamji, Thomas Sundberg, Nathanael S. Gray, Ramnik Xavier, Stuart L. Schreiber, Hwan Geun Choi, Yanke Liang
  • Patent number: 9632089
    Abstract: The present invention includes compounds that are useful in perturbing or disrupting the function of a transmembrane or intracellular protein, whereby binding of the compounds to the transmembrane or intracellular protein induces proteasomal degradation of the transmembrane or intracellular protein. The present invention further includes a method of inducing proteasomal degradation of a transmembrane or intracellular protein. The present invention further includes a method of identifying or validating a protein of interest as a therapeutic target for treatment of a disease state or condition.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: April 25, 2017
    Assignee: Yale University
    Inventors: Craig M. Crews, Hyun Seop Tae, Ashley R. Schneekloth, Taavi Neklesa, Thomas Sundberg
  • Publication number: 20170067874
    Abstract: The present invention includes compounds that are useful in perturbing or disrupting the function of a transmembrane or intracellular protein, whereby binding of the compounds to the transmembrane or intracellular protein induces proteasomal degradation of the transmembrane or intracellular protein. The present invention further includes a method of inducing proteasomal degradation of a transmembrane or intracellular protein.
    Type: Application
    Filed: November 4, 2016
    Publication date: March 9, 2017
    Inventors: Craig M. Crews, Hyun Seop Tae, Ashley R. Schneekloth, Taavi Neklesa, Thomas Sundberg
  • Patent number: 9500653
    Abstract: The present invention includes compounds that are useful in perturbing or disrupting the function of a transmembrane or intracellular protein, whereby binding of a compound to the transmembrane or intracellular protein induces proteasomal degradation of the transmembrane or intracellular protein. The present invention further includes a method of inducing proteasomal degradation of a transmembrane or intracellular protein. The present invention further includes a method of identifying or validating a protein of interest as a therapeutic target for treatment of a disease state or condition.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: November 22, 2016
    Assignee: Yale University
    Inventors: Craig M. Crews, Hyun Seop Tae, Ashley R. Schneekloth, Taavi Neklesa, Thomas Sundberg
  • Publication number: 20140302523
    Abstract: The present invention includes compounds that are useful in perturbing or disrupting the function of a transmembrane or intracellular protein, whereby binding of a compound to the transmembrane or intracellular protein induces proteasomal degradation of the transmembrane or intracellular protein. The present invention further includes a method of inducing proteasomal degradation of a transmembrane or intracellular protein. The present invention further includes a method of identifying or validating a protein of interest as a therapeutic target for treatment of a disease state or condition.
    Type: Application
    Filed: December 6, 2011
    Publication date: October 9, 2014
    Applicant: Yale University
    Inventors: Craig M. Crews, Hyun Seop Tae, Ashley R. Schneekloth, Taavi Neklesa, Thomas Sundberg
  • Publication number: 20070040351
    Abstract: The present invention relates to a motorcycle anti-tipover device that has telescoping support arms that extend to the ground. The support arms are automatically extending when the motorcycle is stationary or moving at low speeds to prevent the motorcycle from tipping over. The telescoping support arms may also serve as a traditional kickstand, or may be used to lift the motorcycle during servicing. Alternatively, an airbag may be deployed underneath the motorcycle to prevent the motorcycle from tipping over.
    Type: Application
    Filed: June 26, 2006
    Publication date: February 22, 2007
    Inventors: Dennis Bozung, Thomas Sundberg, Kelly Osborne